In Wednesday’s Wall Street session, Humacyte Inc (NASDAQ:HUMA) shares traded at $2.34, down -6.02% from the previous session.
HUMA stock price is now 24.26% away from the 50-day moving average and -44.51% away from the 200-day moving average. The market capitalization of the company currently stands at $362.98M.
On December 20, 2024, H.C. Wainwright reiterated its ‘Buy’ rating on the stock by increasing its target price from $12 to quote $15, while ‘Piper Sandler’ rates the stock as ‘Neutral’
In other news, Scheessele William John, Chief Commercial Officer bought 6,493 shares of the company’s stock on Apr 14 ’25. The stock was bought for $9,999 at an average price of $1.54. Upon completion of the transaction, the Chief Commercial Officer now directly owns 22,018 shares in the company, valued at $51522.12. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 10 ’25, CFO and Chief Corp. Deve. Off. Sander Dale A. bought 20,000 shares of the business’s stock. A total of $30,600 was incurred on buying the stock at an average price of $1.53. This leaves the insider owning 40,600 shares of the company worth $95004.0. A total of 18.94% of the company’s stock is owned by insiders.
During the past 12 months, Humacyte Inc has had a low of $1.15 and a high of $9.97. As of last week, the company has a debt-to-equity ratio of 2.28, a current ratio of 3.68, and a quick ratio of 3.28.
The net profit margin was -15481.62% and return on equity was -257.38% for HUMA. For the current quarter, analysts expect HUMA to generate $935.86k in revenue.
